Updated:
StoneCalibre
Brian Wall founded StoneCalibre in 2012 to acquire corporate divestitures and build them permanently.
StoneCalibre
StoneCalibre was formed in 2012 by Brian Wall and operates from Los Angeles with additional offices in Paris and London. The firm makes control investments exclusively, targeting corporate divestitures, buy-and-builds, and special situations that fall outside the mandate of large strategic owners or time-limited private equity funds. Its investment base is patient, permanent capital without a predefined exit clock. The firm pursues a generalist mandate with demonstrated expertise in healthcare, technology, industrials, and business services. Its primary modes are corporate divestitures — non-core assets, complex carve-outs, and regulatory-driven sales from large corporations — plus buy-and-build platform strategies that consolidate fragmented industries through organic and inorganic growth. The portfolio includes the Calibre Scientific life sciences distribution platform, which has completed over forty add-on acquisitions across Europe and North America, most recently acquiring Industrial Glassware (August 2024), Greyhound Chromatography (August 2024), and Camlab Limited (April 2024). Geographic activity spans the United States, United Kingdom, France, Germany, Spain, Switzerland, Brazil, and Italy. StoneCalibre's professional team includes Founder and CEO Brian Wall, CFO John Freeman, Partner Usman Shakeel, and Managing Director Brian Anderson. In January 2024, the Calibre Scientific platform expanded its European presence with the acquisitions of Labtech in the UK and MoBiTec in Germany. The firm maintains patient, long-term capital that allows it to hold investments indefinitely and support management teams through operational transitions without the pressure of a predefined exit timeline. StoneCalibre's structural differentiator is its indefinite-hold capital base paired with a dedicated carve-out skillset. Where conventional private equity funds operate on 10-to-12-year fund lives, forcing a monetization clock, StoneCalibre can buy a non-core division from a Fortune 500 company, stand it up as an independent business, and grow it perpetually through add-on acquisitions — executing the roll-up strategy that time-limited capital structures often truncate.
General information
Firm type
Generalist
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Additional offices
Paris, France · London, United Kingdom
Principals
Brian M. Wall
Founder & CEO
John Freeman
CFO
Usman Shakeel
Partner
Brian Anderson
Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at StoneCalibre?
Brian Wall, founder and CEO, leads investment decisions alongside Partner Usman Shakeel and Managing Director Brian Anderson. The firm operates a centralized investment committee model but discloses its four senior professionals as covering deal origination, execution, and portfolio management across North America and Europe.
How is StoneCalibre structured as an investor?
StoneCalibre operates as a private investment firm managing permanent, long-term capital rather than time-bound fund vehicles. Unlike conventional private equity firms, it has no predetermined exit clock on its holdings. This allows the firm to acquire corporate divestitures and special situation assets with the intention of holding and growing them indefinitely through operational support and add-on acquisitions.
What types of deals does StoneCalibre pursue?
The firm targets three deal types. Corporate divestitures — acquiring non-core divisions, product lines, and complex carve-outs from Fortune 500 companies. Buy-and-builds — platform acquisitions in fragmented industries that can consolidate through organic and inorganic growth. Special situations — operational turnarounds, legacy products, financial restructurings, or assets in secular decline requiring new ownership and strategic repositioning.
What investment stages does Calibre Scientific represent?
Calibre Scientific is the life sciences investment platform within StoneCalibre's portfolio. It operates as a global consolidator of laboratory products, diagnostic reagents, and scientific equipment distributors and manufacturers. The platform has executed over forty add-on acquisitions, expanding from its base into the UK, Germany, Switzerland, Spain, Italy, and Brazil, deploying a buy-and-build strategy rather than early-stage venture or growth equity investing.
Where does StoneCalibre deploy capital geographically?
StoneCalibre deploys capital across North America and Europe, with portfolio company activity documented in the United States, United Kingdom, France, Germany, Spain, Switzerland, Italy, and Brazil. The firm maintains direct offices in Los Angeles, Paris, and London to support transatlantic deal origination and portfolio oversight.
Does StoneCalibre participate in fund commitments or only direct deals?
StoneCalibre makes direct control investments exclusively. The firm is not structured as a fund-of-funds or a limited partner in external private equity vehicles. Its approach is to acquire companies through control transactions and operate them directly through subsidiary platforms, with no disclosed activity as an LP in third-party funds.
What is StoneCalibre's posture on co-investments alongside external GPs?
StoneCalibre's disclosed model does not reference co-investments alongside other general partners. The firm positions itself as a direct acquirer of corporate divestitures and special situations, typically structuring transactions to meet both seller objectives and its own permanent-hold strategy, which is structurally different from co-investment alongside time-limited fund vehicles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: